Denali Therapeutics Inc. (DNLI)

15,43 +0,47 (+3,14%) Alla chiusura: 04:00PM EDT

Denali Therapeutics Inc.

161 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 866 8548
https://www.denalitherapeutics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 445

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Ryan J. Watts Ph.D.	Co-Founder, President, CEO & Director	1,15M	3,65M	1976
Dr. Alexander O. Schuth M.D.	Co-Founder, CFO, COO & Secretary	802,29k	1,65M	1973
Dr. Marc Tessier-Lavigne Ph.D.	Co-Founder & Independent Director	57,5k	N/D	1960
Dr. Carole Ho M.D.	Chief Medical Officer & Head of Development	802,29k	N/D	1973
Mr. Tyler M. Nielsen	Senior Vice President of Corporate Finance	N/D	N/D	1978
Dr. Dana Andersen	Chief Technical and Manufacturing Officer	N/D	N/D	N/D
Mr. Joe Lewcock Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Dr. Laura Hansen	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Chris Walsh	General Counsel	N/D	N/D	N/D
Mr. Mark Rowen	Vice President of Corporate Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Denali Therapeutics Inc. al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 4; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.